Use of bacteria in anti-cancer therapies.
While a number of valid molecular targets have been discovered for tumours over the past decade, finding an effective way of delivering therapeutic genes specifically to tumours has proved more problematic. A variety of viral and non-viral delivery vehicles have been developed and applied in anti-cancer gene therapies. However, these suffer from either inefficient and/or short-lived gene transfer to target cells, instability in the bloodstream and inadequate tumour targeting. Recently, various types of non-pathogenic obligate anaerobic and facultative anaerobic bacteria have been shown to infiltrate and selectively replicate within solid tumours when delivered systemically. This has prompted the development of cancer gene therapy protocols that use such bacteria as gene delivery vehicles. Here, we review the evidence for the success of these in pre-clinical models and clinical trials, as single modality treatments and in combination with conventional cancer therapies.
Ryan
Rachel M
RM
Tumour Targeting Group, Division of Genomic Medicine, University of Sheffield, UK.
Green
Jeffrey
J
Lewis
Claire E
CE
D000818:Animals; D001419:Bacteria / Q000235:genetics* / Q000378:metabolism*; D015687:Cell Hypoxia; D002986:Clinical Trials as Topic; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000235:genetics; D006801:Humans; D009369:Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000382:microbiology / Q000628:therapy*